Table of Contents
Chapter 1.Executive Summary
1.1.Market Snapshot
1.2.Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
1.2.1.Hyperphosphatemia Therapeutics Market, by Region, 2020-2030 (USD Billion)
1.2.2.Hyperphosphatemia Therapeutics Market, by Drug Class, 2020-2030 (USD Billion)
1.2.3.Hyperphosphatemia Therapeutics Market, by Distribution Channel, 2020-2030 (USD Billion)
1.3.Key Trends
1.4.Estimation Methodology
1.5.Research Assumption
Chapter 2.Global Hyperphosphatemia Therapeutics Market Definition and Scope
2.1.Objective of the Study
2.2.Market Definition & Scope
2.2.1.Industry Evolution
2.2.2.Scope of the Study
2.3.Years Considered for the Study
2.4.Currency Conversion Rates
Chapter 3.Global Hyperphosphatemia Therapeutics Market Dynamics
3.1.Hyperphosphatemia Therapeutics Market Impact Analysis (2020-2030)
3.1.1.Market Drivers
3.1.1.1.Increasing public awareness and improved diagnostic capabilities
3.1.1.2.Rising prevalence of chronic kidney disease (CKD)
3.1.2.Market Challenges
3.1.2.1.Complications from use of hyperphosphatemia therapeutics
3.1.2.2.Poor medical adherence
3.1.3.Market Opportunities
3.1.3.1.Rising development of innovative hyperphosphatemia treatment options
3.1.3.2.Increasingly implementing reimbursement policies
Chapter 4.Global Hyperphosphatemia Therapeutics Market Industry Analysis
4.1.Porter's 5 Force Model
4.1.1.Bargaining Power of Suppliers
4.1.2.Bargaining Power of Buyers
4.1.3.Threat of New Entrants
4.1.4.Threat of Substitutes
4.1.5.Competitive Rivalry
4.2.Porter's 5 Force Impact Analysis
4.3.PEST Analysis
4.3.1.Political
4.3.2.Economical
4.3.3.Social
4.3.4.Technological
4.3.5.Environmental
4.3.6.Legal
4.4.Top investment opportunity
4.5.Top winning strategies
4.6.COVID-19 Impact Analysis
4.7.Disruptive Trends
4.8.Industry Expert Perspective
4.9.Analyst Recommendation & Conclusion
Chapter 5.Global Hyperphosphatemia Therapeutics Market, by Drug Class
5.1.Market Snapshot
5.2.Global Hyperphosphatemia Therapeutics Market by Drug Class, Performance - Potential Analysis
5.3.Global Hyperphosphatemia Therapeutics Market Estimates & Forecasts by Drug Class 2020-2030 (USD Billion)
5.4.Hyperphosphatemia Therapeutics Market, Sub Segment Analysis
5.4.1.Sevelamer
5.4.2.Calcium-based Phosphate Binders
5.4.3.Lanthanum Carbonate
5.4.4.Iron-based Phosphate Binders
5.4.5.Others
5.4.6.Non-Phosphate Binders
Chapter 6.Global Hyperphosphatemia Therapeutics Market, by Distribution Channel
6.1.Market Snapshot
6.2.Global Hyperphosphatemia Therapeutics Market by Distribution Channel, Performance - Potential Analysis
6.3.Global Hyperphosphatemia Therapeutics Market Estimates & Forecasts by Distribution Channel 2020-2030 (USD Billion)
6.4.Hyperphosphatemia Therapeutics Market, Sub Segment Analysis
6.4.1.Hospital Pharmacies
6.4.2.Retail Pharmacies
6.4.3.Online Pharmacies
Chapter 7.Global Hyperphosphatemia Therapeutics Market, Regional Analysis
7.1.Top Leading Countries
7.2.Top Emerging Countries
7.3.Hyperphosphatemia Therapeutics Market, Regional Market Snapshot
7.4.North America Hyperphosphatemia Therapeutics Market
7.4.1.U.S. Hyperphosphatemia Therapeutics Market
7.4.1.1.Drug Class breakdown estimates & forecasts, 2020-2030
7.4.1.2.Distribution Channel breakdown estimates & forecasts, 2020-2030
7.4.2.Canada Hyperphosphatemia Therapeutics Market
7.5.Europe Hyperphosphatemia Therapeutics Market Snapshot
7.5.1.U.K. Hyperphosphatemia Therapeutics Market
7.5.2.Germany Hyperphosphatemia Therapeutics Market
7.5.3.France Hyperphosphatemia Therapeutics Market
7.5.4.Spain Hyperphosphatemia Therapeutics Market
7.5.5.Italy Hyperphosphatemia Therapeutics Market
7.5.6.Rest of Europe Hyperphosphatemia Therapeutics Market
7.6.Asia-Pacific Hyperphosphatemia Therapeutics Market Snapshot
7.6.1.China Hyperphosphatemia Therapeutics Market
7.6.2.India Hyperphosphatemia Therapeutics Market
7.6.3.Japan Hyperphosphatemia Therapeutics Market
7.6.4.Australia Hyperphosphatemia Therapeutics Market
7.6.5.South Korea Hyperphosphatemia Therapeutics Market
7.6.6.Rest of Asia Pacific Hyperphosphatemia Therapeutics Market
7.7.Latin America Hyperphosphatemia Therapeutics Market Snapshot
7.7.1.Brazil Hyperphosphatemia Therapeutics Market
7.7.2.Mexico Hyperphosphatemia Therapeutics Market
7.8.Middle East & Africa Hyperphosphatemia Therapeutics Market
7.8.1.Saudi Arabia Hyperphosphatemia Therapeutics Market
7.8.2.South Africa Hyperphosphatemia Therapeutics Market
7.8.3.Rest of Middle East & Africa Hyperphosphatemia Therapeutics Market
Chapter 8.Competitive Intelligence
8.1.Key Company SWOT Analysis
8.2.Top Market Strategies
8.3.Company Profiles
8.3.1. Sanofi SE
8.3.1.1.Key Information
8.3.1.2.Overview
8.3.1.3.Financial (Subject to Data Availability)
8.3.1.4.Product Summary
8.3.1.5.Recent Developments
8.3.2.Takeda Pharmaceutical Company Limited
8.3.3.Lupin Limited
8.3.4.Astellas Pharma Inc.
8.3.5.Akebia Therapeutics, Inc.
8.3.6.CSL Limited
8.3.7.Ardelyx Inc.
8.3.8.Unicycive Inc.
8.3.9.Amag Pharmaceuticals Inc
8.3.10.Akebia Therapeutics Inc.
Chapter 9.Research Process
9.1.Research Process
9.1.1.Data Mining
9.1.2.Analysis
9.1.3.Market Estimation
9.1.4.Validation
9.1.5.Publishing
9.2.Research Attributes
9.3.Research Assumption